SalioGen Therapeutics: Funding, Investors & Team (Oct 2026)
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.
SalioGen Therapeutics has raised $115M across 1 funding round on record, the most recent a Series B of $115M announced in Jan 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SalioGen Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2022.
SalioGen Therapeutics Funding Rounds
SalioGen Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
SalioGen Therapeutics Funding Compared to Other Biotechnology Startups
SalioGen Therapeutics' latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SalioGen Therapeutics in Biotechnology and Burlington
Companies Similar to SalioGen Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
SalioGen Therapeutics Funding FAQs
What does SalioGen Therapeutics do?
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.
How much funding has SalioGen Therapeutics raised?
SalioGen Therapeutics has raised $115M across 1 round on record. The most recent is a Series B of $115M announced in Jan 2022.
When did SalioGen Therapeutics last raise funding?
SalioGen Therapeutics' most recent funding round on record is a Series B of $115M, announced in Jan 2022.
Who is the CEO of SalioGen Therapeutics?
Ray Tabibiazar is listed as CEO at SalioGen Therapeutics.
Where is SalioGen Therapeutics headquartered?
SalioGen Therapeutics is based in Burlington, Massachusetts, United States.
How many employees does SalioGen Therapeutics have?
SalioGen Therapeutics is in the 11-50 employee band.
How does SalioGen Therapeutics' funding compare to other Biotechnology startups?
SalioGen Therapeutics' latest round of $115M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's SalioGen Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SalioGen Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.